Octreotide Scintigraphy Periprocedural Care

Updated: Jun 02, 2022
  • Author: Bishnu Prasad Devkota, MD, MHI, FRCS(Edin), FRCS(Glasg), FACP, FAMIA; Chief Editor: Mahan Mathur, MD  more...
  • Print
Periprocedural Care

Pre-Procedure Planning and Patient Preparation

The patient’s pertinent history should be obtained, including type of suspected primary or metastatic tumor, endocrine status, results of other imaging modalities (eg, CT, MRI, tumor biomarkers), and history of chemotherapy, radiation therapy, recent surgery, and octreotide therapy. Cholecystectomy history should also be obtained. [2]

Patients should be well hydrated before and for at least 1 day after injection to decrease radiation exposure. Octreotide therapy should be stopped for 1 day before 111In pentetreotide administration, while the patient is monitored for signs of withdrawal. When the abdomen is the area of interest, laxatives should be given to clean the bowels. A mild oral laxative should be used on the evening before and after injection. The necessity for bowel preparation should be determined individually, and of course, laxatives should not be administered to patients with diarrhea. [2]